Inorganic Chemical
Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial
Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology
Sands Capital Successfully Raises $555 Million for Third Life Sciences Venture Fund
Sands Capital, life sciences, venture fund, fundraising, healthcare investments, biotechnology, medical technology, pharmaceuticals, healthcare innovation.
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
New York Attorney General Demands Enhanced Safety Labeling for Pediatric Use of Singulair
Singulair, United States Food and Drug Administration, Pediatric brand name, Child, Lawyer (occupation)